In 2022, combinations of insulin human/insulin isophane human cost about 37 U.S. dollars on average, compared to about 21 U.S. dollars in 2021. This statistic shows the average out-of-pocket cost of combined insulin human and insulin isophane human in the U.S. from 2014 to 2022, in U.S. dollars.

This statistic displays the total number of items of insulin prescribed for diabetes in England from 2005/06 to 2023/24. The number of insulin items prescribed has increased to around 8.4 million in 2023/24, compared to 8.1 million in the previous year.

Descriptive statistics for the average insulin administration dose and plasma insulin and glucose levels in open- and closed-loop (N = 14).

DesignA cross-sectional, web-based survey design was employed, consisting of validated self-report measures designed to capture demographic information, insulin use, diabetes-related distress, disordered eating, and body shape perception.Inclusion/Exclusion criteria. Participants were eligible to participate if they self-described as being aged 18 or over, with a diagnosis of Type 1 diabetes and on a prescribed insulin regimen. They were required to be at least one-year post-diagnosis, as people who have been prescribed insulin for less than one year may not have settled into a routine with insulin management and may mismanage their insulin unintentionally. Additionally, participants were required to reside within the UK, as this removed a potential confound of cost or resources as a barrier to accessing insulin. People with a diagnosis of type 2 diabetes were excluded from the study, as the pathophysiology and treatment of the two illnesses are quite different. For example, as those with type 2 diabetes still produce some degree of insulin naturally, non-adherence to an insulin regimen is likely to have less of an immediate impact than for those with type 1 diabetes, who produce no insulin naturally (Peyrot et al., 2010). Potential participants were provided with a link to the study which provided detailed information about the study, details of informed consent and their right to withdraw. When the survey was completed, or participants chose to exit, a debrief page was presented with signposts towards various supports and resources. Participants were offered the opportunity to receive a brief summary of findings from the study and given the chance to win a £25 Amazon gift voucher, both of which required an email address to be supplied through separate surveys, so as to protect the confidentiality of responses. Ethical approval for this study was granted by the chair of the relevant Ethics Committee.Statistical AnalysisPrior to beginning the study, an estimate of the minimum number of participants required was calculated using statistical power tables (Clark-Carter, 2010) and G*Power version 3.1. Based on previous research (Ames, 2017), a medium effect size (.5) was used to calculate sample sizes with a power of .8 (Clark-Carter, 2010), which generated a necessary sample size of 208. All analyses were adequately powered.Data were analysed using IBM SPSS Statistics for Mac version 25. MeasuresDemographic Information. This section collected basic demographic information, including age; gender; country of residence; and current or historical diagnosis of an eating disorder. The data were screened to ensure participants met the inclusion criteria.Insulin Measure. A 16-item questionnaire has been designed to assess rates and reasons for insulin non-adherence (Ames, 2017). Eating Disorder Psychopathology. The Eating Disorder Examination-Questionnaire (EDE-Q) assesses eating disorder psychopathology, and data from this measure was key to informing the primary research questions. It was designed as a self-report version of the interview-based Eating Disorders Examination (EDE; 32), which is considered to be the gold standard measure (Fairburn, Wilson, & Schleimer, 1993). The EDE-Q assesses four subscales: Restraint, Eating Concern, Shape Concern, and Weight Concern. It was found to be an adequate alternative to the EDE (Fairburn & Beglin, 1994). Body Shape Questionnaire (BSQ). The Body Shape Questionnaire is a 34-item self-report measure, designed to assess concerns regarding body shape and the phenomenological experience of “feeling fat” (Cooper, Taylor, Cooper, & Fairbum, 1987). The BSQ targets body image as a central feature of both AN and BN and thus is a useful supplementary measure of eating disorder psychopathology. Diabetes Distress. The Diabetes Distress Scale (Polonsky et al., 2005) is a 17-item scale designed to measure diabetes-related emotional distress via four domains: emotional burden, physician distress, interpersonal distress and regimenn distress. This measure was included on the basis of results from Ames (Ames, 2017), which identified diabetes-related emotional distress as a key reason for insulin non-adherence in type 1 diabetes. Inclusion in this study allowed for further investigation of its role.

The Basal Insulin (Long-Acting Insulin) market plays a crucial role in the management of diabetes, primarily for patients requiring consistent blood glucose control throughout the day and night. Long-acting insulin is designed to provide a steady release of insulin over an extended period, helping to maintain basal

This statistic shows the estimated market revenue of human insulin products worldwide from 2015 to 2021. For 2021, the global market revenue for such products is estimated to be around 44 billion U.S. dollars.

Statistics illustrates consumption, production, prices, and trade of Medicaments Containing Insulin But Not Antibiotics in United States Minor Outlying Islands from 2007 to 2024.

Graph and download economic data for Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Insulin/Antidiabetes Products (PCU3254123254121112) from Jan 1961 to Apr 2025 about pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

This is an overview of the treatment and demographics of 227,435 adults with type 1 diabetes. From 2019 to 2022 glucose control in people with type 1 diabetes in England and Wales improved while blood pressure control deteriorated. Use of diabetes technology (wearable glucose monitoring devices in England and insulin pumps in England and Wales) was associated with lower glucose levels. Diabetes technology was used less by those in the most deprived groups and in ethnic minorities. 30% of people with type 1 diabetes did not attend specialist care in 2021-22 and were less likely to receive annual checks or achieve treatment targets as recommended by the National Institute for Health and Care Excellence (NICE). There are 3 recommendations for commissioners of care.

Global Insulin Biosimilars Market size was valued at USD 2.67 billion in 2022 and is poised to grow from USD 2.80 billion in 2023 to USD 4.07 billion by 2031, growing at a CAGR of 4.8% in the forecast period (2024-2031).

Statistics illustrates consumption, production, prices, and trade of Medicaments Containing Insulin But Not Antibiotics in Chad from 2007 to 2024.

The insulin pump and supplies market has emerged as a critical segment within the diabetes management industry, providing innovative solutions for individuals requiring insulin therapy. An insulin pump is a small, computerized device that continuously delivers insulin to glucose-monitoring patients, allowing for bet

The Premixed Human Insulin market stands as a pivotal segment within the broader diabetes care industry, offering a critical solution for patients managing their blood glucose levels. Characterized by its combination of short-acting and intermediate-acting insulin, premixed human insulin simplifies diabetes manageme

In 2022, combinations of human insulin and insulin isophane human were prescribed over 2.2 million times. In the year before, the number of such prescriptions stood at around 2.8 million. This statistic shows the annual number of insulin human/insulin isophane human combination prescriptions in the U.S. from 2014 to 2022, in millions.

The Smart Insulin Patch market is rapidly emerging as a game-changer in diabetes management, offering innovative solutions that enhance patient care and streamline the administration of insulin. By incorporating advanced technologies such as continuous glucose monitoring and automated drug delivery, smart insulin pa

The Insulin Glargine market plays a critical role in diabetes management, providing a long-acting insulin solution that helps millions of patients achieve better glycemic control. As a biosynthetic insulin analog, Insulin Glargine offers a consistent release of insulin, mimicking the body's natural insulin productio

The Insulin Sensitizers market plays a crucial role in the management of insulin resistance and various metabolic disorders, particularly in the context of growing global diabetes prevalence. These pharmaceutical agents, which enhance the body's sensitivity to insulin, are vital in treating conditions such as type 2

The number of diabetics worldwide in 2021 was 537 million. That number is expected to grow until at least the year 2045. The projected number of diabetics is expected to reach 783 million by that time. With an increased number of diabetics, the prevalence of diabetes is also projected to increase to around 12 percent by 2045.

Diabetes prevalence globally

Diabetes is a chronic disease that affects the production and use of insulin in the body which affects blood glucose. Diabetes comes in two types, type 1 and type 2, which require different types of medical treatments. Globally, China, followed by India, has the largest number of diabetics as of 2021. Despite having the highest number of diabetics, China is not among the countries with the highest prevalence. French Polynesia, followed by Mauritius, had the highest prevalence of diabetics worldwide as of 2021.

Diabetes pharmaceuticals

Treatment for diabetes includes insulin, a hormone that regulates blood glucose, and pills to help regulate the effectiveness of insulin. Treatment depends on the type of diabete. The top drug for the treatment of diabetes, based on market share in 2017, was NovoRapid by Novo Nordisk. NovoRapid is a rapid-acting insulin marketed for both children and adults.

Among the sampling hospitals in China, insulin glargine - a long-acting insulin analogue - held a share of 35 percent in human insulin and insulin analogues market in 2018. Insulin therapy is mainly used to treat type 1 diabetes in which pancreas no longer produce enough or any insulin to lower blood sugar level. The market size of human insulin and insulin analogs in China was projected to expand with a compound annual growth rate of 4.4 percent until 2030.

Statistics illustrates consumption, production, prices, and trade of Medicaments Containing Insulin But Not Antibiotics in Isle of Man from 2007 to 2024.